A lot is riding on Amarin's (NASDAQ: AMRN)long-awaited cardiovascular outcomes study for its triglyceride-lowering drug, Vascepa, and according to management, the trial's data should be available later this year. If the trial demonstrates that Vascepa reduces the risk of cardiovascular events, including death, then it could finally allow management to deliver on what were once blockbuster expectations for this drug.
Boom-or-Bust News Is On Tap Soon for Amarin
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться